Home / Business and Economy / AI Powers New Cancer Drug Discovery Deal
AI Powers New Cancer Drug Discovery Deal
2 Sep
Summary
- Owkin's AI platform licensed to Boehringer Ingelheim.
- Focus on accelerating cancer and immunity disease drug discovery.
- Deal expands on a successful pilot project from 2025.
AI company Owkin has announced a significant licensing agreement with German pharmaceutical giant Boehringer Ingelheim. This partnership aims to expedite the development of new treatments for cancer and immunity-related diseases.
Boehringer Ingelheim will gain access to Owkin's proprietary AI research platform, known as 'K Pro,' along with valuable patient data. This collaboration is an extension of a pilot project initiated in 2025. During that project, Owkin utilized patient tumor samples and biological datasets to assist Boehringer Ingelheim in identifying promising drug targets.
Under the new pact, Owkin will provide multimodal oncology data to Boehringer Ingelheim and will also generate novel data within the field of immunology. Owkin's model involves licensing, sourcing, and generating patient data through its extensive global network. The financial terms of this agreement were not disclosed.
